(Q37359613)

19 August 2017

1 reference

title

Pharmacology and antifungal properties of anidulafungin, a new echinocandin (English)

1 reference

19 August 2017

1 reference

ChEBI release 2020-05-28

1 reference

4

Thomas J Walsh

1 reference

19 August 2017

Kristina E Estes

1

1 reference

19 August 2017

Scott R Penzak

series ordinal

2

1 reference

19 August 2017

Karim Anton Calis

series ordinal

3

1 reference

19 August 2017

language of work or name

English

0 references

publication date

1 January 2009

1 reference

19 August 2017

1 reference

19 August 2017

volume

29

1 reference

19 August 2017

issue

1

1 reference

19 August 2017

page(s)

17-30

1 reference

Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study

19 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Safety and pharmacokinetics of intravenous anidulafungin in children with neutropenia at high risk for invasive fungal infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Safety, tolerability, and pharmacokinetics of Micafungin (FK463) in febrile neutropenic pediatric patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Morphological effects of lipopeptides against Aspergillus fumigatus correlate with activities against (1,3)-beta-D-glucan synthase

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Morphological changes of Candida albicans induced by micafungin (FK463), a water-soluble echinocandin-like lipopeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

In vitro antifungal activity of Micafungin (FK463) against dimorphic fungi: comparison of yeast-like and mycelial forms

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Serum differentially alters the antifungal properties of echinocandin drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

In vivo efficacy of anidulafungin and caspofungin against Candida glabrata and association with in vitro potency in the presence of sera

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Comparative antifungal activities and plasma pharmacokinetics of micafungin (FK463) against disseminated candidiasis and invasive pulmonary aspergillosis in persistently neutropenic rabbits

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Pharmacodynamics of caspofungin in a murine model of invasive pulmonary aspergillosis: evidence of concentration-dependent activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

In vivo pharmacodynamic characterization of anidulafungin in a neutropenic murine candidiasis model.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Escape of Candida from caspofungin inhibition at concentrations above the MIC (paradoxical effect) accomplished by increased cell wall chitin; evidence for beta-1,6-glucan synthesis inhibition by caspofungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Attenuation of the activity of caspofungin at high concentrations against candida albicans: possible role of cell wall integrity and calcineurin pathways.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Antifungal efficacy of caspofungin (MK-0991) in experimental pulmonary aspergillosis in persistently neutropenic rabbits: pharmacokinetics, drug disposition, and relationship to galactomannan antigenemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Pharmacokinetic and pharmacodynamic modeling of anidulafungin (LY303366): reappraisal of its efficacy in neutropenic animal models of opportunistic mycoses using optimal plasma sampling

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Single- and multiple-dose pharmacokinetics of caspofungin in healthy men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Echinocandin antifungal drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Lack of pharmacokinetic interaction between anidulafungin and tacrolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Efficacies of two new antifungal agents, the triazole ravuconazole and the echinocandin LY-303366, in an experimental model of invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Anidulafungin versus fluconazole for invasive candidiasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

In vitro synergy testing of anidulafungin with itraconazole, voriconazole, and amphotericin B against Aspergillus spp. and Fusarium spp.

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Combination antifungal therapy for invasive aspergillosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Combination of voriconazole and caspofungin as primary therapy for invasive aspergillosis in solid organ transplant recipients: a prospective, multicenter, observational study

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

Safety and pharmacokinetics of coadministered voriconazole and anidulafungin

21 January 2018

1 reference

https://api.crossref.org/works/10.1592%2FPHCO.29.1.17

21 January 2018

Identifiers

DOI

10.1592/PHCO.29.1.17

1 reference

19 August 2017

1 reference